Emapunil

A TSPO agonist that raises endogenous allopregnanolone to calm anxiety, the leading proof of concept for benzodiazepine-free anxiolysis rather than a neurosteroid itself.

Emapunil (AC-5216, XBD173) is an investigational selective TSPO (18 kDa translocator protein) ligand that promotes neurosteroid synthesis to produce anxiolytic effects, and in early human and animal studies it produced rapid anti-anxiety and anti-panic action without the sedation, dependence, or withdrawal that characterize benzodiazepines. That neurosteroid-driven, GABA-potentiating mechanism appears to sidestep the classic benzodiazepine side-effect burden in the limited data available.

However, the honest limitation is that safety information comes from preclinical work and small early-phase human studies rather than large controlled trials, so detailed adverse-event and long-term risk data do not exist. It was not advanced to market, meaning no regulatory label or established contraindications are on record. Its human risk profile should therefore be regarded as promising but under-characterized, appropriate to treat as experimental.

Emapunil began as AC-5216, a mitochondrial benzodiazepine receptor ligand characterised by Kita and colleagues at Dainippon Sumitomo Pharma in 2004, who reported antianxiety and antidepressant-like effects in rodents. It was subsequently advanced into human development under the code XBD-173 and the proposed name emapunil. The compound gained prominence with a 2009 Science paper by Rupprecht and colleagues, which demonstrated that it produced anxiolysis in both animal models and a human CCK-4 panic-induction paradigm while sparing the sedation, tolerance, and withdrawal of benzodiazepines. It reached Phase 2 clinical evaluation, but development for anxiety was ultimately discontinued. The molecule has since remained a reference compound in TSPO pharmacology, and interest has revived around its potential in depression, neuroinflammation, and neurodegeneration.

Within neuropharmacology, emapunil is regarded as a foundational proof of concept that anxiolysis can be achieved by boosting endogenous neurosteroids rather than by directly potentiating GABA-A receptors, an approach that promised the efficacy of benzodiazepines without their liabilities. Its 2009 Science report is heavily cited and helped legitimise TSPO as a psychiatric drug target. Because it never reached market, it is not a consumer compound; it circulates in research and nootropics discussion chiefly as the archetype of a benzodiazepine-free anxiolytic. Contemporary reviews continue to position it, alongside etifoxine and newer TSPO ligands, as a template for neurosteroid-based treatment of anxiety, depression, and inflammatory brain disease.